By Josh White
Date: Tuesday 03 Feb 2026
(Sharecast News) - Merck & Co reported better-than-expected fourth-quarter results on Tuesday, driven by continued strength in its oncology franchise and animal health division, but shares slipped after the drugmaker issued a 2026 outlook that fell short of market expectations as it braced for patent expiries and generic competition.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 121.93 |
| Change Today | $ 2.18 |
| % Change | 1.82 % |
| 52 Week High | $122.66 |
| 52 Week Low | $73.47 |
| Volume | 13,083,323 |
| Shares Issued | 2,527.64m |
| Market Cap | $308,195m |
| Beta | 0.01 |
| RiskGrade | 92 |
| Strong Buy | 8 |
| Buy | 10 |
| Neutral | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 15:59 | 247 @ $121.89 |
| 15:59 | 100 @ $121.88 |
| 15:59 | 100 @ $121.89 |
| 15:59 | 100 @ $121.95 |
| 15:59 | 120 @ $121.95 |
You are here: research